Molecular Cancer Therapeutics
Overview
Molecular Cancer Therapeutics is a leading scientific journal that focuses on the latest advancements in cancer research and therapeutic strategies at the molecular level. It publishes cutting-edge studies on targeted therapies, drug development, and personalized medicine, providing valuable insights into the molecular mechanisms of cancer and potential treatments. This journal serves as a vital resource for researchers, clinicians, and pharmaceutical professionals working towards improving cancer treatment outcomes.
Details
Details
Abbr.
Mol Cancer Ther
Start
2001
End
Continuing
Frequency
Monthly
p-ISSN
1535-7163
e-ISSN
1538-8514
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 730
199
SJR / Ranks: 960
2270
CiteScore / Ranks: 1344
10.30
JIF / Ranks: 1231
5.7
Recent Articles
11.
Lundgren Mortensen A, Berglund H, Jha P, Stenman A, Selvaraju R, Lundqvist H, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39976160
Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for...
12.
Nguyen J, Naara S, Woerner L, VanLandingham N, Hoerner M, Santuray R, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39976130
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of PTEN (phosphatase and tensin homolog deleted on chromosome 10) is one of the most common...
13.
Reyes-Gonzalez J, Rajkumar H, Lee W, Baidoo K, Edinger R, Diehl G, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39911068
Radiopharmaceutical therapy (RPT) is a promising approach to treating solid tumors, but therapeutic advances are impeded by the lack of broadly expressed targets and shared molecular vulnerability across different tumor...
14.
Matkar S, East M, Stuhlmiller T, Witek G, Farrel A, Pastor S, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39907037
Mutations in the tyrosine kinase domain of the Anaplastic Lymphoma Kinase (ALK) oncogene in neuroblastoma occur most frequently at one of three hotspot amino acid residues, with the F1174* and...
15.
Zhang W, Wang J, Shi W, Qiu H, Ke S, Tian Y, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39895587
In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma patients with signet ring cell carcinoma or peritoneal metastasis, were enrolled to receive 8 cycles...
16.
Simoneau A, Pratt C, Wu H, Rajeswaran S, Comer C, Sudsakorn S, et al.
Mol Cancer Ther
. 2025 Jan;
PMID: 39886906
Inhibition of the deubiquitinating enzyme USP1 can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD) and represents a novel therapeutic strategy for the treatment of BRCA1/2 mutant...
17.
Puleo N, Ram H, Dziubinski M, Carvette D, Teitel J, Sekhar S, et al.
Mol Cancer Ther
. 2025 Jan;
PMID: 39873147
Up to 90% of high-grade serous ovarian cancer (HGSC) patients will develop resistance to platinum-based chemotherapy, posing substantial therapeutic challenges due to a lack of universally druggable targets. Leveraging BenevolentAI's...
18.
Martires L, Ahronian L, Pratt C, Das N, Zhang X, Whittington D, et al.
Mol Cancer Ther
. 2025 Jan;
PMID: 39868490
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on poly(ADP-ribose) polymerase (PARP) inhibitors, which are subject to high rates of innate or acquired resistance in patients. Here, we used CRISPR/Cas9-based...
19.
Nelson K, Reil K, Tsuji S, Parikh A, Robinson M, House C, et al.
Mol Cancer Ther
. 2025 Jan;
PMID: 39868467
In situ immunization (ISI) has emerged as a promising approach to bolster early phases of the cancer immunity cycle through improved T cell priming. One class of ISI agents, oncolytic...
20.
Lin Y, Lin K, Fu Q, Sun X, Wang H, Su L, et al.
Mol Cancer Ther
. 2025 Jan;
PMID: 39851063
TIGIT and PVRIG are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as...